Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donafenib
- Development stage
- Phase 4
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Donafenib is an orally available small molecule multikinase inhibitor developed for the treatment of various cancers, most notably unresectable hepatocellular carcinoma. It is a deuterated derivative of sorafenib with improved pharmacokinetic properties. Donafenib inhibits multiple kinases, including Raf kinase and several receptor tyrosine kinases such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). By blocking these targets, donafenib disrupts key signaling pathways involved in tumor cell proliferation and survival. The drug was first approved in China in June 2021 for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy[1][2][4][7][8].
- Brand names
- ZepsunZeprosenZeprosyn
- Other names
- Sorafenib-d3Sorafenib-d-3Sorafenib-d 3Donafenib tosylate
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR1/2/3 (Vascular endothelial growth factor receptor 1 (VEGFR1) / Vascular endothelial growth factor receptor 2 (VEGFR2) / Vascular endothelial growth factor receptor 3 (VEGFR3))KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on donafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donafenib.